Dr. Rahul Kushwah reports

PREDICTMEDIX AI ANNOUNCES CLOSING OF $460,150 FIRST TRANCHE

Predictmedix AI Inc. has successfully closed the first tranche of its non-brokered private placement. The company issued 9,203,000 units at an issue price of five cents per unit, raising gross proceeds of $460,150. Notably, $60,000 of the tranche was subscribed by insiders, with Sheldon Kales and Dr. Rahul Kushwah each participating for $30,000, highlighting strong internal confidence in Predictmedix's future growth and innovation.

The company issued 9,203,000 units at a price of five cents per unit, raising $460,150 in this tranche. Each unit consists of one common share of Predictmedix and one-half of one common share purchase warrant. Each warrant will entitle the holder thereof to purchase one half common share of the company at a price of 15 cents for a period of 36 months following the closing date of the offering. If, following four months and a day after the closing date, the volume weighted average price of the common shares on the CSE is equal to or greater than 30 cents for any 10 consecutive trading days, the corporation may, upon providing written notice to the holders of warrants, accelerate the expiry date of the warrants to the date that is 30 days following the date of such written notice.

Insiders' participation in the private placement constitutes a related party transaction pursuant to Multilateral Instrument 61-101, Protection of Minority Security Holders in Special Transactions. The company is relying on the exemption from the valuation and minority shareholder approval requirements under MI 61-101, as the fair market value of the insiders' participation in the private placement does not exceed 25 per cent of the market capitalization of the company.

All securities issued in connection with the private placement are subject to a statutory hold period of four months and one day from the date of issuance.

Strategic context and investor engagement

This financing round comes on the heels of Predictmedix's active engagement with European capital markets. Most recently, the company participated in the 25th MK Investment Conference in Munich, Germany, a premier gathering of investors, family offices and private-market deal makers focused on AI (artificial intelligence), longevity, tech and ESG (environmental, social and governance) themes. In parallel, earlier this year, Predictmedix advanced its investor outreach via a high-profile European road show, engaging influential family offices and institutional investors. These engagements reflect the company's deliberate strategy to expand its shareholder base and build relationships among global investors aligned with its AI health technology mission.

Details of the company's recent product validations, pilot programs and strategic partnerships can be found in earlier news releases available on the company's website.

About Predictmedix AI Inc.

Predictmedix AI is an emerging provider of rapid health screening and remote patient care solutions globally. The company's Smarthealth AI stations -- powered by a proprietary artificial intelligence (AI) -- use multispectral cameras to analyze physiological data patterns and predict a variety of health issues, including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes.

We seek Safe Harbor.